Form 8-K - Current report:
SEC Accession No. 0001213900-20-021164
Filing Date
2020-08-10
Accepted
2020-08-10 16:13:47
Documents
7
Period of Report
2020-08-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea125100-8k_citiuspharma.htm 8-K 28450
2 AMENDED AND RESTATED UNDERWRITING AGREEMENT BETWEEN CITIUS PHARMACEUTICALS, INC. ea125100ex1-1_citius.htm EX-1.1 244691
3 FORM OF UNDERWRITER WARRANT ea125100ex4-1_citius.htm EX-4.1 108166
4 OPINION OF WYRICK ROBBINS YATES & PONTON, LLP ea125100ex5-1_citius.htm EX-5.1 8626
5 PRESS RELEASE DATED AUGUST 5, 2020 ea125100ex99-1_citius.htm EX-99.1 8535
6 PRESS RELEASE DATED AUGUST 5, 2020 ea125100ex99-2_citius.htm EX-99.2 8675
7 PRESS RELEASE DATED AUGUST 10, 2020. ea125100ex99-3_citius.htm EX-99.3 8682
  Complete submission text file 0001213900-20-021164.txt   417175
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 201089519
SIC: 2834 Pharmaceutical Preparations